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Summary The aim of this study was to assess whether qualitative or semi-quantitative detection of human
papillomavirus type 16 (HPV 16) can help to identify women with major grade cervical intraepithelial
neoplasia (CIN 2 and CIN 3) among those referred with a smear suggesting mild dyskaryosis. The study
population consisted of 200 women sequentially attending the Royal Free Hospital colposcopy clinic. All
women were investigated by cytology, colposcopy and, where appropriate, histopathology, and HPV 16 DNA
was detected in cervical scrape samples using the polymerase chain reaction (PCR). A final clinical diagnosis of
normal, wart virus infected (WVI), CIN 1, CIN 2 or CIN 3 was made in 179 women. On the basis of the
qualitative PCR data, the presence of HPV 16 DNA was of borderline use in identifying women with high
grade cervical disease [63/113 (normal/WVI/CIN 1) vs 46/66 (CIN 2/CIN 3); P = 0.065]. However, semi-
quantitative PCR analysis showed that a high/medium HPV 16 result was significantly associated with
high-grade disease [29/113 (normal/WVI/CIN 1) vs 38/66 (CIN 2/CIN 3); P = 0.0001]. Furthermore, semi-
quantitative PCR and cytology were performed on the repeat smear taken immediately prior to colposcopy.
The combined laboratory results show that 53/60 women with biopsy proven high-grade disease were
identified, as were 26/95 women who were either normal or who had low grade cervical disease. The possibility
of using such an approach for selecting women for more rapid or for routine colposcopy appointments in the
two groups respectively is discussed.
The natural history of squamous cancer of the uterine cervix
resembles that of a sexually transmitted disease (Kessler II,
1976). Potential aetiological agents include the transforming
members of the human papillomaviruses, in particular HPV
types 16 and 18, since a high proportion of patients with
cervical intraepithelial neoplasia (CIN) and invasive carcin-
oma of the cervix are infected with these HPV types (zur
Hausen, 1987; Cornelisson et al., 1989). In contrast, the
prevalence of HPV 16 based on rigorous polymerase chain
reaction (PCR) studies in women with no evidence of cervical
disease is between 5-17% (Van den Brule et al., 1991; Bavin
et al., 1992). Complementary to the epidemiological investi-
gations linking HPV 16 and cervical cancer, in vitro studies
have shown that HPV 16 is capable of immortalising trans-
formed cell lines through the E6 and E7 protein products
binding to the cellular tumour suppressor genes p53 and
plO5RB respectively (Dyson et al., 1989; Scheffner et al.,
1991). Recent data (Crook et al., 1992) have shown that in
women with cervical carcinoma, mutations in p53 and the
presence of HPV 16 or 18 DNA are mutually exclusive, thus
confirming similar data obtained from analysis of established
cervical cancer cell lines (Crook et al., 1991; Scheffner et al.,
1991).
In addition to a possible role in the aetiology of cervical
carcinoma, the presence of HPV 16 DNA may be of use as a
prognostic marker of high-grade cervical disease, i.e. CIN 2
and CIN 3. Previous work in our laboratory (Bavin et al.,
1992) has shown that the presence of HPV 16 DNA is useful
in identifying women with high-grade cervical disease within
a general practice population with an associated relative risk
of 5.67. In addition, the combination of cytology and
HPV 16 positivity identified more women with significant
disease than either screening method alone. However, the
clinical setting which would most benefit from a prognostic
marker of high-grade cervical disease is in the large number
of women referred for colposcopy with a smear suggesting
mild dyskaryosis. We have previously shown (Giles et al.,
1989) that approximately one third of these women will have
high-grade disease whilst the remainder will have either
CIN 1 or be colposcopically normal. A mechanism to differ-
entiate women with high-grade disease within such a referral
population would have a significant impact on targeting
colposcopic resources to those individuals at high risk.
Recent use of a semi-quantitative PCR method (Cuzick et al.,
1992) has suggested that the presence of high or intermediate
quantities of HPV 16 DNA in cervical scrapes is useful in
identifying women with high-grade cervical disease within
populations referred with a mild or moderately dyskaryotic
smear. However, it should be noted that the data provided
for the population referred with a mildly dyskaryotic smear
contained relatively small numbers of women (23 in total).
Therefore, we report here the qualitative and semi-quanti-
tative PCR assessment of HPV 16 DNA in a population of
200 women referred with a smear suggesting mild dyskary-
osis. We reasoned that such analyses on such a large cohort
should enable a critical evaluation of the whether the mere
presence or, as suggested by Cuzick and coworkers, the
amount of HPV 16 DNA is a useful marker of high-grade
cervical disease in such populations.
Subjects and methods
The study group was composed of 200 patients sequentially
attending the Royal Free Hospital colposcopy clinic, referred
with a smear report suggesting mild dyskaryosis. The clinical
details of this population have been described elsewhere
(Giles et al., 1989). Following colposcopy and histopathology
of directed biopsies when appropriate, a final diagnosis was
made in 179 women. Of these, 54 had no evidence of cervical
disease, 14 had evidence of wart virus infection, 45 had
CIN 1, 31 had CIN 2 and 35 had CIN 3. The mean age for
the population was 29 years (mean age of women with CIN:
26.9 years; mean age of women with no evidence of cervical
abnormality: 33.5 years).
Two cervical scrapes were taken from each patient; one for
standard cytological analysis and the second placed in 10 ml
of cold phosphate buffered saline. The cells from the latter
sample were harvested by centrifugation and the DNA ex-
tracted with SDS-Proteinase K lysis and purified by phenol/
Correspondence: P.G. Walker, University Department of Gynaeco-
logy, The Royal Free Hospital, Pond Street, London NW3 2PF,
UK.
Received 22 June 1992; and in revised form 21 October 1992.
'." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 67, 602-605USE OF HPV16 FOR DETECTING CERVICAL CANCER 603
chloroform extraction and ethanol precipitation. PCR was
performed using a Hybaid Thermal Reactor (HBTR1) as
described previously (Bavin et al., 1992). The oligonucleotide
primers were designed to amplify a 223 base pair region of
the HPV 16 E6 and E7 genes (nucleotides 491-714). The
PCR system routinely detected five genome copies of HPV 16
and did not amplify closely related HPV types. Semi-quan-
tiative PCR analysis was effected using the procedure
described by Cuzick et al. (1992) and amplified signals strati-
fied into high, medium, low or negative.
In each PCR experiment, appropriate positive and negative
controls were included to verify the results and to avoid false
positive signals due to contamination. Analysis of each sam-
ple was performed on two separate occasions using DNA
extracted from coded cervical scrapes (Bavin et al., 1992).
Samples in which discrepant results were obtained were sub-
jected to two further PCR analyses to ensure that the original
positive signal was not due to contamination. Correlation of
the HPV 16 status with clinical diagnosis was not effected by
the authors who had been involved in the PCR analysis.
Statistical analysis of the distribution of results was deter-
mined using x2 analysis. The relative risk of having high-
grade disease and HPV 16 was calculated by dividing the
incidence rate of disease in the HPV 16 positive (or HPV 16
DNA high/medium) group by the incidence rate of disease in
the HPV 16 negative (or HPV 16 DNA low/negative) group.
Results
A PCR assay was used to detect HPV 16 DNA in cervical
scrape samples derived from 179 women referred to a colpo-
scopy clinic with a smear suggesting mild dyskaryosis. The
overall prevalence of HPV 16 in the study population was
61%. The qualitative and semi-quantitative PCR analysis for
HPV 16 DNA in each group within the population is shown
in Table I. The results show that a high/medium quantity of
HPV 16 DNA is more likely to be associated with higher
grades of cervical disease whereas the qualitative analysis is
confounded by the presence of HPV 16 in a high proportion
of women with no evidence of cervical disease.
Stratification of the study group into those with either
high-grade disease (CIN 2/CIN 3) or those with mild or no
evidence of disease allows the effectiveness of both the qua-
litative and semi-quantitative PCR for HPV 16 to be evalu-
ated to identify women in the former group. The results of
these analyses are shown in Table II. Whereas the qualitative
detection of HPV 16 DNA was of borderline significance in
identifying women with high-grade disease (P = 0.067) the
presence of high/medium quantities of HPV 16 DNA was
significantly associated with the presence of high-grade cer-
vical disease (P = 0.0001). The relative risks associated with
HPV 16 DNA and high-grade disease for the qualitative
assay was 1.48 (95% confidence limits; 0.96-2.27) and for
the semi-quantitative assay was 2.27 (95% confidence limits;
1.57-3.33).
The repeat cytology results at the time of colposcopy
coupled with a semi-quantitative HPV 16 DNA results in
TableII Abilityofthequalitativeandsemi-quantitative HPV 16DNA
results todiscriminate between womenwitheitherlow-grade, wartvirus
infection or no evidence of disease and those with high-grade disease
Normal/WVI CIN I CIN2/CIN3
HPV 16 DNA (n = 113) (n = 66)
Qualitative
Positive 63 (55.8%) 46 (69.7%)
Negative 50 (44.2%) 20 (30.3%)
Semi-quantitative
High/medium 29 (25.7%) 38 (57.6%)
Low/negative 84 (74.3%) 28 (42.4%)
Qualitative PCR: X2 = 3.4; P = 0.065.
x = 18.12; P=0.0001.
Semi-quantitative PCR:
Table III Ability of a combination of repeat cytology at the time of
colposcopy suggesting high-grade disease and/or high/medium quan-
tities of HPV 16 DNA with the final diagnosis. 155 of the 179 women
had satisfactory repeat cytology to be included in the analysis
HPV16 DNA high/medium
and/or repeat cytology
Final diagnosis CIN2/CIN3 Totals
CIN 3 (n = 30)/CIN 2 27 (90%)a; CIN 3 53/60
(n = 30) 26 (87%)b; CIN 2
Normal/WVI (n = 57)/ 13 (23%); Normal/WVI 26/95c
CIN 1 (n = 38) 13 (34%); CIN 1
Total (n = 155) 79 (51%) 79/155
aThe three women not identified had repeat cytology result sugges-
ting: CIN 1(1), WVI (1)andnormal(1)."Thefourwomennotidentified
had repeat cytology result suggesting: CIN 1 (3) and WVI (1).
CP<0. 0001
women with a final diagnosis of normal/CIN 1/WVI, CIN 2
or CIN 3 are shown in Table III. These data are based on
the 155 women who had a satisfactory repeat cytology result.
The sensitivity, specificity, positive and negative predictive
values for the presence of high/medium amounts of HPV 16
DNA or the combination of repeat cytology suggestive of
CIN 2/CIN 3 and/or the presence of a high/medium quantity
of HPV 16 DNA are shown in Table IV. The sensitivity of
detecting women with high-grade cervical disease is increased
when both criteria are used (0.89 vs 0.58) without affecting
specificity (0.73 vs 0.76). Likewise, the negative predictive
value associated with using both criteria is significantly in-
creased (0.89 vs 0.74).
Discussion
W^e have assessed whether HPV 16 DNA can be a useful
discriminator to identify women with high-grade disease
(CIN 2/CIN 3) in a group referred to a colposcopy clinic
with a smear suggesting mild dyskaryosis. The primary
analysis revealed that the qualitative detection of HPV 16
Table I Correlation ofqualitative and semi-quantitative analysis for HPV 16 DNA
with final diagnosis in 179 women
HPV 16 Normal WVI CIN I CIN2 CIN3 Total
DNA (n = 54) (n = 14) (n = 45) (n = 31) (n = 35) (n = 179)
Qualitative
Positive 34 5 24 20 26 109
(63%) (35.6%) (53.5%) (64.5%) (74.3%) (61%)
Negative 20 9 21 11 9 70
(37%) (63.4%) (46.5%) (35.5%) (25.7%) (39%)
Semi-quantitative
High/medium 17 0 12 15 23 67
(31%) (0%) (27%) (48.4%) (66%) (37.4%) Low/negative 37 14 33 16 12 112
(69%) (100%) (73%) (51.6%) (34%) (62.6%)604 P.J. BAVIN et al.
Table IV Prognostic associations between laboratory results and high-grade
disease for the 155 women with satisfactory repeat cytology at time of colpos-
copy
HPV 16 DNA
high/medium and/or
HPV16 DNA repeat cytology
Parameter high/medium CIN2/CIN 3 Significance
Sensitivity 0.58 (35/60) 0.89 (52/60) P = 0.0005
Specificity 0.76 (72/95) 0.73 (69/95) N.S.
Positive predictive value 0.60 (35/58) 0.67 (53/79) N.S.
Negative predictive value 0.74 (72/97) 0.89 (59/66) P= 0.017
DNA using PCR was of borderline assistance in identifying
women with high-grade disease. This is because HPV 16
infection is common in women who have previously had a
mildly dyskaryotic smear, even if they are colposcopically
normal at the time of examination. Interestingly, the rate of
HPV 16 infection in this group of women is similar to that
found by Schneider and colleages (54%; Scneider et al.,
1987). The high prevalence of HPV 16 in the apparently
normal group impairs the ability of qualitative assays for
HPV 16 to identify women with current high-grade disease.
On the basis of recent data suggesting that high or inter-
mediate levels of HPV 16 DNA may be useful to idenitify
women with high-grade disease, our population was re-exam-
ined using the semi-quantitative methods described by Cuzick
and colleagues (1992). The results clearly demonstrated that a
high/medium quantity of HPV 16 DNA is significantly asso-
ciated with high-grade cervical disease whilst women with
either CIN 1 or who are normal are more likely to be
HPV 16 DNA low or negative (P = 0.0001). It is interesting
to note that the proportion of women with high-grade
disease who possessed high/medium levels of HPV 16 DNA
was similar to that previously reported (Cuzick et al., 1992),
in which relatively small numbers of women were available
for analysis. The major effect of using the discriminator of
high/medium quantities of HPV 16 DNA is to reduce the
number of women identified within the group who have a
final diagnosis of CIN I/WVI/normal rather than increase
the detection of women with high-grade disease.
We have previously shown that, in a general practice sett-
ing, the combination of cytology and qualitative presence of
HPV 16 DNA identified more women with high-grade
disease than either test alone (Bavin et al., 1992). Current
management of women referred with a smear suggesting mild
dyskaryosis involves a repeat smear analysis at the time of
colposcopy. One system for patient management would be to
perform semi-quantitative PCR for HPV 16 and cytology on
this specimen and only colposcope those women with either
smears suggesting high-grade disease and/or high levels of
HPV 16 DNA. In our study population, 155/179 women had
a satisfactory repeat smear and the combination of repeat
cytology and/or of HPV 16 DNA resulted in the
identification of 89% of women with a final diagnosis of
CIN 2/CIN 3. Furthermore, only one of the 60 women with
high-grade disease would have been returned to routine
follow-up. As expected, the combination of assays resulted in
28.5% of women with CIN l/WVI/normal being classified as
requiring rapid colposcopic examination. However, the com-
bination of repeat cytology 6 months after the original smear
suggesting mild dyskaryosis and quantitative assessment of
HPV 16 DNA would result in a 49% decrease in the number
of women referred for colposcopy. Such an approach would
enable colposcopic resources to be targeted at women most
at risk of having high-grade disease without compromising
the detection rate for high-grade disease.
In conclusion, our data confirm and extend those reported
by Cuzick et al. (1992), and indicate the effectiveness of a
combination ofrepeat cytology and semi-quantitative PCR in
identifying women with high-grade disease within the female
population referred with a smear suggesting mild dyskary-
osis. We are currently applying more sophisticated methods
for PCR quantification (Fox et al., 1992) to fully investigate
the levels of HPV 16 DNA present in cervical scrapes and its
correlation with future development of cervical disease.
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